Kim, Minsoo
Gorelick, Alexander N. http://orcid.org/0000-0001-6736-8246
Vàzquez-García, Ignacio http://orcid.org/0000-0003-0427-2639
Williams, Marc J. http://orcid.org/0000-0001-5524-4174
Salehi, Sohrab
Shi, Hongyu
Weiner, Adam C. http://orcid.org/0000-0002-5968-3606
Ceglia, Nick
Funnell, Tyler http://orcid.org/0000-0003-1612-5644
Park, Tricia http://orcid.org/0000-0003-4471-004X
Boscenco, Sonia
O’Flanagan, Ciara H.
Jiang, Hui http://orcid.org/0000-0003-1869-1607
Grewal, Diljot
Tang, Cerise
Rusk, Nicole http://orcid.org/0000-0003-2663-6288
Gammage, Payam A. http://orcid.org/0000-0003-1968-1726
McPherson, Andrew
Aparicio, Sam http://orcid.org/0000-0002-0487-9599
Shah, Sohrab P. http://orcid.org/0000-0001-6402-523X
Reznik, Ed http://orcid.org/0000-0002-6511-5947
Funding for this research was provided by:
Susan G. Komen (SAC220206)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30-CA008748, R37-CA276200, R37-CA276200)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1-HG011014)
U.S. Department of Defense (W81XWH-18-1-0318)
Article History
Received: 21 June 2022
Accepted: 20 March 2024
First Online: 13 May 2024
Competing interests
: S.P.S. has an advisory role to AstraZeneca. S.A. is a founder and shareholder of GenomeTherapeutics (Inflex) and scientific advisor to Sangamo Therapeutics, Chordia Biosciences and the Institute of Cancer Research, London. All roles are outside the scope of this manuscript. The remaining authors declare no competing interests.